.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
McKesson
Deloitte
Cipla
McKinsey
Harvard Business School
Daiichi Sankyo
Accenture
US Department of Justice
Mallinckrodt

Generated: June 27, 2017

DrugPatentWatch Database Preview

Claims for Patent: 7,615,573

« Back to Dashboard

Claims for Patent: 7,615,573

Title:Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
Abstract: Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.
Inventor(s): Siegel; Craig (Woburn, MA), Shayman; James A. (Ann Arbor, MI), Nelson; Carol A. (Westford, MA), Harris; David J. (Lexington, MA), Copeland; Diane P. (North Billerica, MA)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI) Genzyme Corporation (Cambridge, MA)
Application Number:11/702,425
Patent Claims: 1. A method of inhibiting glucosylceramide synthase or lowering glycosphingolipid concentrations in a subject in need thereof, comprising administering to the subject an effective amount of a compound represented by the following structural formula: ##STR00032## or a physiologically acceptable salt thereof.

2. The method of claim 1, wherein the compound has an enantiomeric excess of at least 25%.

3. The method of claim 1, wherein the compound has an enantiomeric excess of at least 50%.

4. The method of claim 1, wherein the compound has an enantiomeric excess of at least 90%.

5. The method of claim 1, wherein the compound has an enantiomeric excess of at least 99%.

6. A method of treating a subject with Fabry disease, comprising administering to the subject an effective amount of a compound represented by the following structural formula: ##STR00033## or a physiologically acceptable salt thereof.

7. The method of claim 6, wherein the compound has an enantiomeric excess of at least 25%.

8. The method of claim 6, wherein the compound has an enantiomeric excess of at least 50%.

9. The method of claim 6, wherein the compound has an enantiomeric excess of at least 90%.

10. The method of claim 6, wherein the compound has an enantiomeric excess of at least 99%.

11. A method of inhibiting glucosylceramide synthase or lowering glycosphingolipid concentrations in a subject in need thereof, comprising administering to the subject an effective amount of a compound represented by the following structural formula: ##STR00034## or a physiologically acceptable salt thereof.

12. The method of claim 11, wherein the compound has an enantiomeric excess of at least 25%.

13. The method of claim 11, wherein the compound has an enantiomeric excess of at least 50%.

14. The method of claim 11, wherein the compound has an enantiomeric excess of at least 90%.

15. The method of claim 11, wherein the compound has an enantiomeric excess of at least 99%.

16. A method of treating a subject with Fabry disease, comprising administering to the subject an effective amount of a compound represented by the following structural formula: ##STR00035## or a physiologically acceptable salt thereof.

17. The method of claim 16, wherein the compound has an enantiomeric excess of at least 25%.

18. The method of claim 16, wherein the compound has an enantiomeric excess of at least 50%.

19. The method of claim 16, wherein the compound has an enantiomeric excess of at least 90%.

20. The method of claim 16, wherein the compound has an enantiomeric excess of at least 99%.

21. A method of treating a subject with Gaucher disease, comprising administering to the subject an effective amount of a compound represented by the following structural formula: ##STR00036## or a physiologically acceptable salt thereof.

22. The method of claim 21, wherein the compound has an enantiomeric excess of at least 25%.

23. The method of claim 21, wherein the compound has an enantiomeric excess of at least 50%.

24. The method of claim 21, wherein the compound has an enantiomeric excess of at least 90%.

25. The method of claim 21, wherein the compound has an enantiomeric excess of at least 99%.

26. A method of treating a subject with Gaucher disease, comprising administering to the subject an effective amount of a compound represented by the following structural formula: ##STR00037## or a physiologically acceptable salt thereof.

27. The method of claim 26, wherein the compound has an enantiomeric excess of at least 25%.

28. The method of claim 26, wherein the compound has an enantiomeric excess of at least 50%.

29. The method of claim 26, wherein the compound has an enantiomeric excess of at least 90%.

30. The method of claim 26, wherein the compound has an enantiomeric excess of at least 99%.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Baxter
Julphar
McKesson
Healthtrust
Moodys
UBS
Citi
Colorcon
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot